A PHASE-I CLINICAL-TRIAL OF A PROTRACTED CONTINUOUS-INFUSION OF 5-FLUOROURACIL WITH ORAL FOLINIC ACID IN PATIENTS WITH UNRESECTABLE ADENOCARCINOMA OF THE COLON OR RECTUM
- Authors:
- Published online on: July 1, 1995 https://doi.org/10.3892/ijo.7.1.191
- Pages: 191-194
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Studies of the mechanism of action of 5-fluorouracil (5-FU) suggest that maximal inhibition of the target enzyme thymidylate synthase can be achieved with a protracted infusion of 5-FU and oral leucovorin. We report the results of a phase I study in which seven patients with advanced colorectal cancer were treated with a 30-day continuous infusion of 5-FU and a fixed 50 mg dose of oral folinic acid every 6 hours. The 5-FU dose started at 100 mg/m(2)/day with planned escalations of 50 mg/m(2)/day. The qualitative toxic effects observed included diarrhea, mucositis, and hand/foot syndrome. These toxic effects were manageable at 100 mg/m(2)/day, but became dose-limiting at 150 mg/m(2)/day with two of four patients unable to complete the planned 30-day infusion. No objective responses were observed, but minor activity was documented in two patients. We recommend a starting dose of 125 mg/m(2)/day for subsequent phase II trials of this regimen in patients with colorectal cancer.